Biolegend, 100339, Ultra-LEAF™ Purified anti-mouse CD3ε Antibody, 100μg

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Armenian Hamster
Immunogen: H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality tested IHC-F, IP, Activ, Block, WB, ICC - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional Product Notes: Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more… View more applications data for this product in our Scientific Poster Library.
Application References(PubMed link indicates BioLegend citation): Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block) Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ) Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB) Payer E, et al. 1991. J. Immunol. 146:2536. (IF) Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD) Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ) Henrickson M, et al. 1995. Transplantation 60:828. (Deplete) Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete) Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete) Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block) Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ) Ko SY, et al. 2005. J. Immunol. 175:3309. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F) Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F) Wang W, et al. 2007. J. Immunol. 178:4885. (Activ) Xiao S, et al. 2007. J. Exp. Med. 204:1691. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Kenna TJ, et al. 2008. Blood 111:2091. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed Schulteis RD, et al. 2008. Blood 295:G273. PubMed Qi Q, et al. 2009. Blood 114:564. PubMed Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed Yan J, et al. 2014. Vaccine. 32:2833. PubMed Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations: Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed Aso K, et al. 2023. Nat Commun. 14:984. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed Wang Y, et al. 2023. iScience. 26:106630. PubMed Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed Wang T, et al. 2023. Commun Biol. 6:613. PubMed Roy S, et al. 2023. J Clin Invest. 133:. PubMed Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed Chen J, et al. 2022. Neoplasma. 69:1129. PubMed Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed Zhang H, et al. 2022. J Clin Invest. 132: . PubMed Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed Romine KA, et al. 2023. Leukemia. 37:580. PubMed Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed Ye L, et al. 2022. Cell Metab. 34:595. PubMed Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed Denk D, et al. 2022. Immunity. 55:2059. PubMed Li Q, et al. 2022. Cell Rep. 40:111308. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Qi Z, et al. 2022. Nat Commun. 13:182. PubMed Wang W, et al. 2020. Cell Rep. 107936:32. PubMed Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed Krone A, et al. 2022. Sci Rep. 218:. PubMed Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed Huang Y, et al. 2020. FASEB J. 34:1768. PubMed Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed Stump CT, et al. 2021. Open Biol. 11:210245. PubMed He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed Codina A, et al. 2019. Cell Syst. 8:136. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed Glassman CR, et al. 2021. eLife. 10:00. PubMed Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed Saragovi A, et al. 2020. Elife. 9:00. PubMed Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Han K, et al. 2021. Nat Metab. 3:318. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed Yuan X, et al. 2017. Elife. 6:e29540. PubMed Takahashi F, et al. 2022. iScience. 25:104278. PubMed Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed Woo MS, et al. 2021. J Exp Med. :218. PubMed Minns D, et al. 2021. Nat Commun. 12:1285. PubMed Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed Xu Y, et al. 2021. iScience. 24:103445. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed Konishi Y, et al. 2018. iScience. 10:98. PubMed Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed Wang F, et al. 2021. Nat Commun. 12:1378. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_11150783 (BioLegend Cat. No. 100339) AB_11149115 (BioLegend Cat. No. 100340) AB_2616673 (BioLegend Cat. No. 100359) AB_2616674 (BioLegend Cat. No. 100360) AB_2800555 (BioLegend Cat. No. 100371) AB_2800556 (BioLegend Cat. No. 100372)
Structure: Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function: TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor: Peptide antigen/MHC-complex
Cell Type: NKT cells, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules, TCRs
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.
Gene ID: 12501
UniProt: View information about CD3epsilon on UniProt.org
Clone: 145-2C11
Regulatory Status: RUO
Other Names: CD3ε, T3, CD3
Isotype: Armenian Hamster IgG
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.